Gilead Sciences, Inc. and EVOQ Therapeutics, Inc. announced a collaboration and licensing
agreement to advance EVOQ's proprietary technology for the treatment of rheumatoid arthritis (RA) and lupus. EVOQ's
NanoDisc technology is designed to enable lymph-targeted delivery of disease-specific antigens and has the potential to
change the paradigm for the treatment of autoimmune diseases. Under the agreement, Gilead and EVOQ will collaborate on
preclinical development. Gilead has the option to exclusively license rights to EVOQ's NanoDisc technology to pursue
product candidates for RA and lupus indications and will be responsible for clinical development and commercialization.